Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 30, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 14.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 30, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 15, 2027 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | Trial Milestone | Phase 3 |
| March 31, 2029 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome | Trial Milestone | Phase 2 |
Track STOK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open STOK in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.